Compare Monolithic Power Systems Inc (MPWR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Tango Therapeutics Inc. — how do they compare? Monolithic Power Systems Inc trades at $1,224.47 (market cap $64.85B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Monolithic Power Systems Inc is far larger — about 17.3× Tango Therapeutics Inc.'s market cap, and Monolithic Power Systems Inc pays a 0.61% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Tango Therapeutics Inc. for 0 Days on average.
| MPWR | TNGX | |
|---|---|---|
Market Cap | $64.85B | $3.75B |
Volume | 692,538 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $1.69K | $32.90 |
52-Week Low | $856.96 | $7.50 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $63.45B | $2.77B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,319.55 with minimal daily movement (+0.02%) amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, 24.5% net margins, and robust revenue growth from $2.8B to $3.3B year-over-year. Recent news highlights CEO share sales and a manufacturing partnership with GlobalFoundries to support AI and data center demand. Valuation remains elevated with P/E at 80.5 and P/S at 19.7, reflecting high growth expectations.
The outlook remains positive given analyst consensus (88% buy ratings) and a $1,830 price target, but risks include premium valuation compression, insider selling, and dependence on AI infrastructure growth. Cash flow strength supports dividend payments, though technical weakness near key support at $1,300 requires monitoring for sustained bullish momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
